Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV. Issue 8 (3rd August 2022)
- Record Type:
- Journal Article
- Title:
- Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV. Issue 8 (3rd August 2022)
- Main Title:
- Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV
- Authors:
- Oldfield, Benjamin J.
Li, Yu
Vickers-Smith, Rachel
Becker, William C.
Barry, Declan T.
Crystal, Stephen
Gordon, Kirsha S.
Kerns, Robert D.
Rentsch, Christopher T.
Marshall, Brandon D.L.
Edelman, E. Jennifer - Abstract:
- ABSTRACT: Gabapentin is commonly prescribed for chronic pain, including to patients with HIV (PWH). There is growing concern regarding gabapentin's potential for harm, particularly in combination with opioids. Among PWH, we examined factors associated with higher doses of gabapentin receipt and determined if receipt varied by opioid use. We examined data from the Veterans Aging Cohort Study, a national prospective cohort including PWH, from 2002 through 2017. Covariates included prescribed opioid dose, self-reported past year opioid use, and other sociodemographic and clinical variables. We used multinomial logistic regression to determine independent predictors of gabapentin receipt. Among 3, 702 PWH, 902 (24%) received any gabapentin during the study period at a mean daily dose of 1, 469 mg. In the multinomial model, high-dose gabapentin receipt was associated with high-dose benzodiazepine receipt (adjusted odds ratio [aOR], 95% confidence interval [CI]= 1.53, [1.03–2.27]), pain interference (1.65 [1.39–1.95]), and hand or foot pain (1.81, [1.45–2.26]). High-dose gabapentin receipt was associated with prescribed high-dose opioids receipt (2.66 [1.95–3.62]) but not self-reported opioid use (1.03 [0.89–1.21]). PWH prescribed gabapentin at higher doses are more likely to receive high-dose opioids and high-dose benzodiazepines, raising safety concerns.
- Is Part Of:
- AIDS care. Volume 34:Issue 8(2022)
- Journal:
- AIDS care
- Issue:
- Volume 34:Issue 8(2022)
- Issue Display:
- Volume 34, Issue 8 (2022)
- Year:
- 2022
- Volume:
- 34
- Issue:
- 8
- Issue Sort Value:
- 2022-0034-0008-0000
- Page Start:
- 1053
- Page End:
- 1063
- Publication Date:
- 2022-08-03
- Subjects:
- Opioid-related disorders -- HIV -- pain -- pharmacoepidemiology -- cohort studies
AIDS (Disease) -- Social aspects -- Periodicals
AIDS (Disease) -- Psychological aspects -- Periodicals
AIDS (Disease) -- Patients -- Care -- Periodicals
Acquired Immunodeficiency Syndrome
362.1969792 - Journal URLs:
- http://www.tandfonline.com/ ↗
- DOI:
- 10.1080/09540121.2021.1939851 ↗
- Languages:
- English
- ISSNs:
- 0954-0121
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0773.083190
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23882.xml